Sandvig-Pharma ApS: Financial statements 2023
CVR: 40667687
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
Sandvig-Pharma ApS (CVR 40667687) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -1,234,540 and a net result of DKK -7,764,469 compared with DKK -572,781 the year before. Equity in the 2023 report amounted to DKK -8,287,867.
- Gross Profit
- DKK -1,234,540
- Profit/Loss
- DKK -7,764,469
- Equity
- DKK -8,287,867
- Total Assets
- DKK 3,426,277
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -1.2 mio. | -7.8 mio. | -8.3 mio. | - |
| 2022 | - | -423 t. | -573 t. | -523 t. | - |
| 2021 | - | - | 0 | 50 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout Sandvig-Pharma ApS
Sandvig-Pharma ApS is a Danish company of the type Anpartsselskab based in Aabenraa, founded in 2019. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Z-Pharma ApS and Zibo Pharma ApS. The management consists of Lars Buchard Denker. The company is owned by Sandvig Capital ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK -4,539,181 and a net result of DKK -3,988,029 compared with DKK -5,566,003 the year before. Equity in the 2025 report amounted to DKK -17,841,900.